Mark A. Velleca, Director at G1 Therapeutics, Inc. (GTHX), sold 39,357 shares at $27.59 ($1.2M) on 2021-02-17, disclosed to the SEC on 2021-02-18.
Open-market sale of $1.2M GTHX by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $34.87 | 8,317 | $290K | 23.9% |
| 2 | $34.87 | 8,317 | $290K | 23.9% |
| 3 | $36.22 | 2,700 | $98K | 8.0% |
| 4 | $37.00 | 23 | $851 | 0.1% |
| 5 | $27.59 | 9,400 | $259K | 21.3% |
| 6 | $28.41 | 600 |
| $17K |
| 1.4% |
| 7 | $26.02 | 10,000 | $260K | 21.4% |
| Total | $30.88 avg | 39,357 | $1.2M | 100% |
| Filing → |
| GTHX | SELL | 2022-09-22 | $270K | — | Filing → |
| GTHX | SELL | 2022-08-18 | $1.0M | — | Filing → |
| GTHX | SELL | 2021-07-15 | $946K | — | Filing → |